Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | F13A1 | P00488 | 3/20 | 0.39 |
| ▸ | TGM2 | P21980 | 3/20 | 0.39 |
| ▸ | TGM1 | P22735 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25555099 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9AF13A1TGM2 | |
| SCHEMBL25555187 | 0.86 | SMN1; SMN2 (0.42) | SMN1; SMN2NPC1RAB9ACYP3A4HTR2C | |
| SCHEMBL25555184 | 0.86 | SMN1; SMN2 (0.42) | SMN1; SMN2NPC1RAB9ACYP3A4HTR2C | |
| SCHEMBL16760681 | 0.82 | — | — | |
| SCHEMBL21285563 | 0.75 | HTR2C (0.38) | HTR2C | |
| SCHEMBL30089149 | 0.74 | CYP3A4 (0.39) | SMN1; SMN2NPC1RAB9ACYP3A4HTR2C | |
| SCHEMBL2493522 | 0.74 | HTR2C (0.45) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL1336851 | 0.74 | HTR2C (0.45) | SMN1; SMN2NPC1RAB9AHTR2CCYP2C19 | |
| SCHEMBL24175974 | 0.73 | TACR1 (0.40) | SMN1; SMN2NPC1RAB9ACYP3A4HTT | |
| SCHEMBL2670172 | 0.73 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1RAB9AF13A1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136582-A1 | SELECT KRAS G12C INHIBITORS AND USES THEREOF | 1200 PHARMA LLC (US) | 2025-05-01 | — | — | US | disclosed |
| CN-119156383-A | Selective KRAS G12C inhibitors and uses thereof | 1200药业有限责任公司 | 2024-12-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136582-A1 | SELECT KRAS G12C INHIBITORS AND USES THEREOF | KRAS, NRAS, HRAS | SMN1; SMN2 1670/4885NPC1 1597/4885RAB9A 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.